Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained ... Kronos Bio, Inc.April 10, 2021 GMT MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742 Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter of 2021 SAN MATEO, ...
Source: apnews.com